Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04493502




Registration number
NCT04493502
Ethics application status
Date submitted
29/07/2020
Date registered
30/07/2020
Date last updated
28/04/2023

Titles & IDs
Public title
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Secondary ID [1] 0 0
I7P-MC-DSAD
Secondary ID [2] 0 0
17497
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hidradenitis Suppurativa 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - LY3041658

Experimental: LY3041658 - Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).

Placebo Comparator: Placebo - Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.


Treatment: Drugs: Placebo
Administered IV

Treatment: Drugs: LY3041658
Administered IV
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count
Timepoint [1] 0 0
Baseline, Week 16
Secondary outcome [2] 0 0
Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)
Timepoint [2] 0 0
Baseline, Week 16

Eligibility
Key inclusion criteria
- Have a diagnosis of HS for at least 6 months

- Have HS lesions in at least 2 different anatomic areas

- Have inadequate response or intolerance to a 28 day course of oral antibiotics

- Have a total count of abscesses and inflammatory nodules greater than or equal to 4

- Agree to use a topical antiseptic daily

- Agree to stop using topical antibiotics during the study. In certain cases, oral
antibiotics will be allowed
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have more than 20 draining fistulae

- Have received any biologic medication (adalimumab, etc.) for the treatment of HS

- Plan to use oral opioids for HS-related pain during the study

- Uncontrolled depression or suicidal thoughts

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/08/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/10/2022
Sample size
Target
Accrual to date
Final
72
Recruitment in Australia
Recruitment state(s)
NSW,QIDVIC,WA
Recruitment hospital [1] 0 0
Westmead Hospital - Northmead
Recruitment hospital [2] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [3] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment hospital [4] 0 0
Fremantle Dermatology - Fremantle
Recruitment hospital [5] 0 0
Holdsworth House Medical Practice - Sydney
Recruitment postcode(s) [1] 0 0
2152 - Northmead
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
03050 - Parkville
Recruitment postcode(s) [4] 0 0
6160 - Fremantle
Recruitment postcode(s) [5] 0 0
2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New Hampshire
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The reason for this study is to see if the study drug LY3041658 is effective in participants
with moderate-to-severe hidradenitis suppurativa (HS).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04493502
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04493502